What's Happening?
MacroGenics, Inc., a clinical-stage biopharmaceutical company, has announced a definitive agreement to sell its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. The transaction includes
the transfer of the manufacturing site, contract development and manufacturing organization (CDMO) operations, and associated personnel to Bora. This move aligns with MacroGenics' strategic priorities to focus on advancing its innovative pipeline and delivering long-term shareholder value. Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing, views this acquisition as a key part of its strategy to expand its North American biologics operation. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.
Why It's Important?
This transaction is significant as it provides MacroGenics with non-dilutive capital to accelerate its pipeline development, potentially leading to key value inflection points in 2026 and beyond. For Bora Pharmaceuticals, the acquisition enhances its capabilities in the North American market, particularly in biologics drug substance and drug product manufacturing. The deal also ensures that MacroGenics maintains access to an expanded array of development and manufacturing capabilities, supporting its current and future pipeline. The transfer of approximately 140 employees to Bora is expected to facilitate a seamless transition and continued service for both MacroGenics and existing CDMO clients.
What's Next?
Following the completion of the transaction, Bora will assume responsibility for MacroGenics' manufacturing operations, including the FDA-approved facility in Rockville, Maryland. MacroGenics will continue to collaborate with Bora through a supply arrangement to support its internal pipeline needs. The companies will work together to ensure a smooth transition and maintain service continuity. The transaction is anticipated to close in the third quarter of 2026, pending the satisfaction of customary closing conditions.
